Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
NCT00372567
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.
- Current treatment with any chemotherapy other than imatinib.
- Current treatment with any dose of imatinib other than 400 mg
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Boston, Massachusetts
- Duarte, California
- Los Angeles, California
- Los Angeles, California
- Pasadena, California
- Santa Monica, California
- Stanford, California
- Washington, District of Columbia
- Miami, Florida
- Tampa, Florida
- Park Ridge, Illinois
- Boston, Massachusetts
- Detroit, Michigan
- Minneapolis, Minnesota
- St. Louis, Missouri
- New York, New York
- New York, New York
- New York, New York
- Durham, North Carolina
- Cleveland, Ohio
- Columbus, Ohio
- Columubs, Ohio
- Portland, Oregon
- Philadelphia, Pennsylvania
- Nashville, Tennessee
- Seattle, Washington
- Seattle, Washington
- Madison, Wisconsin
- Garran, Australian Capital Territory
- Camperdown, New South Wales
- Randwick, New South Wales
- Auchenflower, Queensland
- Ashford, South Australia
- Bedford Park, South Australia
- East Melbourne, Victoria
- Leuven,
- Toronto, Ontario
- Montreal, Quebec
- Lyon,
- Marseille,
- VILLEJUIF Cedex,
- Aviano, PN
- Candiolo, Torino
- Bologna,
- Genova,
- Milano,
- Milano,
- Milano,
- Torino,
- Groningen, Gr
- Rotterdam, ZH
- Singapore,
- Singapore,
- Singapore,
- L'Hospitalet del Llobregat, Barcelona
- Barcelona,
- Madrid,
- Lausanne,
- Sutton, Surrey
- Leeds,
- London,
- Newcastle-Upon-Tyne,
- Detroit, Michigan
- Farmington Hills, Michigan
- Creve Coeur, Missouri
- St. Louis, Missouri
- St. Peters, Missouri
- Philadelphia, Pennsylvania
- Goettingen,
- Hamburg,
- Lai Chi Kok, Kowloon
- Tuen Mun, New Territories
- Hong Kong,
- Bologna,
- Milano,
- San Giovanni Rotondo,
- Seoul,
- Seoul,
- Seoul,
- Barcelona,
- Valencia,
- Glasgow,
- Leeds,
- London,
- London,
- London,
- Manchester,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | |||
Official Title ICMJE | A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib | |||
Brief Summary | A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year. | |||
Detailed Description | The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Gastrointestinal Stromal Tumor | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 69 | |||
Original Enrollment ICMJE | 212 | |||
Actual Study Completion Date ICMJE | November 2009 | |||
Actual Primary Completion Date | November 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany, Hong Kong, Italy, Korea, Republic of, Spain, United Kingdom, United States | |||
Removed Location Countries | France | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00372567 | |||
Other Study ID Numbers ICMJE | A6181112 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |